DPC's Immunoassay Workcell Now Available
July 05 2005 - 7:13PM
Business Wire
Diagnostic Products Corporation (NYSE:DP) today announced that they
have recently begun shipping the Immunoassay Workcell, a high
volume automated immunoassay testing system. An extensive testing
program and a controlled launch plan have proven the reliability of
the system and demonstrated its ability to significantly improve
laboratory productivity. DPC's Sample Management System (SMS) is
used to create the Immunoassay Workcell, which combines two
IMMULITE 2000 systems, two IMMULITE 2500 systems, or a combination
of the two systems. The Immunoassay Workcell is designed to meet
the needs of the high volume testing facilities to provide
flexibility with productivity for immunoassay testing. The system
operator now has access to 48 different assays and 9,600-reagent
tests from a single sample entry point, allowing up to 5 hours of
usable walk-away time. A unique advantage of the Immunoassay
Workcell is that it processes patient samples on a tube-by-tube
basis, as opposed to the more conventional rack loading technique.
The Immunoassay Workcell also simplifies operation by allowing the
laboratory technician to interface with the entire system via a
single workstation. "This is great news for both DPC and our
customers," said Sidney A. Aroesty, President, COO, DPC. "With
approximately 4,000 IMMULITE 2000 and IMMULITE 2500 systems placed
worldwide, it is clear that these systems are meeting the needs of
many laboratories in a variety of testing environments. The
addition of our Immunoassay Workcell will offer even more
flexibility in processing immunoassay tests and will increase
productivity and provide operators more usable walk-away time to
perform other duties in the lab. The fact that the SMS can be
linked to a track-based laboratory automation system further
expands our flexibility to meet the needs of our customers. This is
the 'powerhouse' in the family of IMMULITE systems." About
Diagnostic Products Corporation Diagnostic Products Corporation,
founded in 1971, is the global leader dedicated exclusively to
immunodiagnostics. DPC's product menu includes over 75 immunoassays
and more than 365 specific allergens and allergy panels. In
addition, DPC addresses the chemistry and laboratory automation
testing needs of its customers through partnerships with
manufacturers of chemistry systems and reagents. The combined
chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested.
DPC also designs and manufactures automated laboratory
instrumentation, which provides fast, accurate results while
reducing labor and reagent costs. DPC sells its products to
hospitals, clinics and laboratories in more than 100 countries.
Additional Company information can be found on DPC's website at
www.dpcweb.com. Except for the historical information contained
herein, this press release contains forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially. These factors include the effects of
governmental or other actions relating to the FDA's decision that
its Application Integrity Policy should be applied to the Company
or relating to the Company's Chinese affiliate; the rate of
customer demand for the Company's products; the Company's ability
to successfully market new and existing products; its dependence on
certain suppliers; domestic and foreign government regulation; its
ability to keep abreast of technological innovations and to
translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC
reports and filings.
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From May 2024 to Jun 2024
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Jun 2023 to Jun 2024